DiaMedica Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DMAC research report →
Range $7 – $10
Price Chart
About the company
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes.
- CEO
- Dietrich John Pauls
- IPO
- 2012
- Employees
- 35
- HQ
- Minneapolis, MN, US
Get TickerSpark's AI analysis on DMAC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $445.15M
- P/E
- -10.86
- PEG
- 1.57
- P/S
- 0.00
- P/B
- 15.53
- EV/EBITDA
- -10.92
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -94.47%
- ROIC
- -143.84%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-34,397,000
- Net Income
- $-32,766,000-34.0%
- EPS
- $-0.70-16.7%
- OCF Growth
- -31.6%
- FCF Growth
- -31.7%
- 52W High
- $11.00
- 52W Low
- $5.25
- 50D MA
- $8.35
- 200D MA
- $7.18
- Beta
- 0.94
- RSI (14)
- 42
- Avg Volume
- 206.77K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
DiaMedica said it hit key enrollment milestones in its fetal growth restriction and stroke programs, while cash remains sufficient into Q4 2027 and multiple readouts are approaching.· November 13, 2026
- Completed enrollment in the first 2 cohorts of the investigator-sponsored FGR phase 2 study; 12 participants have been treated so far at 5 and 10 micrograms/kg.
- REMEDY 2 in acute ischemic stroke enrolled its 200th participant in October, triggering the prespecified interim analysis process.
- The company expects the DSMB to complete the stroke interim analysis in Q1 2027 and says the final sample size could range from 300 to 728 participants depending on the observed effect.
- DiaMedica continues prepping additional preeclampsia studies in Canada, the U.K., and potentially the U.S., with FDA feedback still being addressed.
- Cash of $34.9 million at September 30, 2026 is expected to fund planned clinical studies and corporate operations into Q4 2027.
DiaMedica reported cash, cash equivalents and short-term investments of $34.9 million at September 30, 2026, versus $59.9 million at December 31, 2025. Current liabilities were $7.5 million and working capital was $28 million at quarter end, compared with $5.1 million and $55.5 million at year-end 2025. Net cash used in operating activities for the first 9 months of 2026 was $26 million versus $21.3 million in the first 9 months of 2025. R&D expense was $9.2 million in Q3 2026 and $25.4 million for the first 9 months, versus $6.4 million and $17.9 million a year ago. G&A expense was $2.4 million in Q3 and $7.2 million for the first 9 months, versus $2.6 million and $7.3 million. Net loss was $11.3 million, or $0.21 per share, versus $8.6 million, or $0.17 per share last year; 9M net loss was $31.5 million, or $0.58 per share, versus $24 million, or $0.53 per share. Management said cash is expected to fund planned clinical studies and corporate operations into Q4 2027. On guidance, R&D expense is expected to increase moderately as REMEDY 2 enrollment and preeclampsia start-up activities continue, while G&A should remain relatively steady.
Rick Pauls framed the quarter around two clinical milestones: finishing enrollment in the first two FGR cohorts and reaching the 200th patient in REMEDY 2. His tone was constructive and optimistic, emphasizing that these programs are moving DiaMedica closer to readouts that could define the next stage for DM199 in FGR, preeclampsia, and stroke. He also stressed that the company is progressing on U.S. preeclampsia regulatory work and sees a common vascular-biology rationale across indications.
Scott Kellen focused on liquidity, burn, and spending discipline. He said the company ended the quarter with $34.9 million in cash, cash equivalents and short-term investments and expects that to fund operations into Q4 2027. He also walked through the cost drivers: higher R&D from REMEDY 2, preeclampsia study start-up in Canada and the U.K., additional reproductive toxicology work, manufacturing development, and noncash stock comp; G&A was largely stable, with modest declines offset by stock comp and personnel costs.
Analysts pressed for color on the upcoming FGR data, including how birth weight percentile and Doppler measures would be benchmarked, how severe the patients are, and what a meaningful read-through would be for preeclampsia. Management said the data will be compared with historical controls, that the enrolled FGR patients are very severe, and that even stabilization in Doppler measures would be encouraging versus the usual worsening trajectory. On stroke, management said the DSMB will stop the study for futility if there is no drug effect, but if the effect resembles phase 2 they would expect something closer to 300 patients, while a weaker effect could push enrollment toward the high end of 728. They also said first enrollment in the company-sponsored preeclampsia study could still happen this year, but early 2027 is the fallback.
The company now has multiple near-term catalysts: FGR cohort data on November 24, a REMEDY 2 interim analysis in Q1 2027, and continued progress on preeclampsia programs. Management reiterated that DM199 showed blood-pressure and vascular-signal effects in prior preeclampsia work, and they believe positive FGR findings would strengthen the case for early-onset preeclampsia.
The call also highlighted meaningful execution and clinical risk: the FGR program is still very early, with only 12 patients treated and open-label data yet to be presented. REMEDY 2 could still stop for futility if the interim analysis does not show a drug effect, and the final stroke sample size could expand materially to as many as 728 patients if the signal is modest. In preeclampsia, U.S. development still depends on resolving FDA nonclinical feedback.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 46.9%
- Shares Outstanding
- 53.96M
- Float Shares
- 25.33M
of shares held by institutions
92 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cooperman Leon G | 3.45M | 0 |
| Blackrock, Inc. | 2.21M | ▼ 42.96K |
| Geode Capital Management, LLC | 893.83K | ▼ 288 |
| Paragon Associates & Paragon Associates Ii Joint Venture | 875.00K | 0 |
| Millennium Management LLC | 831.08K | ▼ 14.23K |
| Vanguard Group Inc | 723.12K | ▲ 58.55K |
| State Street Corp | 659.73K | ▲ 12.98K |
| Bleichroeder LP | 382.32K | 0 |
| Vanguard Capital Management LLC | 360.56K | ▲ 5.03K |
| Osaic Holdings, Inc. | 330.10K | ▼ 8.01K |
| Northern Trust Corp | 326.30K | ▼ 1.22K |
| Vanguard Portfolio Management LLC | 256.51K | ▲ 4.84K |
Held by 77 ETFs
Biggest fund positions in DMAC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 10, 26 | Pauls Dietrich John | other | 60,200 |
| Jan 2, 26 | Parsons James T. | other | 10,095 |
| Jan 2, 26 | Giuffre Randall Michael | other | 6,175 |
| Jan 2, 26 | Semba Charles Pauling | other | 3,355 |
| Nov 25, 25 | STAHLBERG JAN | buy | 73,099 |
| Nov 24, 25 | STAHLBERG JAN | buy | 40,253 |
| Nov 21, 25 | STAHLBERG JAN | buy | 208,872 |
| Nov 20, 25 | STAHLBERG JAN | buy | 128,426 |
| Nov 19, 25 | STAHLBERG JAN | buy | 240,352 |
| Nov 18, 25 | STAHLBERG JAN | buy | 182,882 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DMAC coverage
Recent articles, reports, and earnings notes.
No research on DMAC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DMAC report →DiaMedica Therapeutics: Maintaining "Buy" DM199 FGR Data November 2026 And AIS Advancement
seekingalpha.com · Nov 16
DiaMedica Therapeutics Inc. (DMAC) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
DiaMedica Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Nov 13
DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
businesswire.com · Nov 12
DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026
businesswire.com · Nov 5
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
gurufocus.com · Oct 22
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
businesswire.com · Oct 22
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
businesswire.com · Oct 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.